Increasing HDL Level Ineffective at Decreasing Cardiovascular Events
Am Fam Physician. 2015 Jan 15;91(2):133-134.
Does treatment aimed at increasing high-density lipoprotein (HDL) levels, in addition to treatment with statins, decrease cardiovascular events and deaths due to any cause?
Being the “good” cholesterol is not the same as being the “useful” cholesterol. Drug therapy aimed at increasing HDL cholesterol levels, when added to statin treatment, does not decrease patients' likelihood of experiencing a cardiovascular event or of dying earlier. (Level of Evidence = 1a)
The researchers searched three databases, including the Cochrane Library, reference lists of previous meta-analyses and reviews, and conference proceedings to find large randomized trials (more than 1,000 patients) that compared drugs aimed at increasing HDL cholesterol levels vs. various interventions that do not increase HDL levels. Two authors independently completed the searches, and three authors extracted the data. They found 11 studies of niacin, 20 studies of fibrates, and eight studies of cholesteryl ester transfer protein (CETP) inhibitors such as anacetrapib and dalcetrapib (this class of drugs is not available in the United States, Canada, or the United Kingdom). All told, the studies enrolled more than 100,000 patients and found that attempting to increase the HDL level conferred no benefit on all-cause mortality, coronary heart disease mortality, or stroke likelihood. The problem, if you want to call it that, is the effect of statins—studies conducted in the current “statin era” do not show an added benefit of trying to bump HDL levels even though early studies of niacin by itself showed a pronounced effect in reducing nonfatal myocardial infarction.
Study design: Meta-analysis (randomized controlled trials)
Funding source: Self-funded or unfunded
Setting: Various (meta-analysis)
Reference: Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ. 2014; 349: g4379.
POEMs (patient-oriented evidence that matters) are provided by EssentialEvidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, please see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.
For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.
To subscribe to a free podcast of these and other POEMs that appear in AFP,search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.
A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Oct 15, 2020
Access the latest issue of American Family Physician